Estela Rodriguez: Keeping up with the press-release literature pre-ASCO24
Estela Rodriguez shared on X:
“Keeping up with the press-release literature pre-ASCO24.
TROPION-lung01 Datopotamab deruxtecan (ADC) showed meaningful (magnitude?) OS advantage vs. chemo in the subgroup of non-squamous NSCLC (but not overall population).” .
Source: Estela Rodriguez/X
Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023